Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans

DNA and Cell Biology

Volumn 29, Issue 10, 2010, Pages 619-624

  Kim, Hyun Jeong ^a   Jin, Xue Mei ^a   Kim, Hee Nam ^a   Lee, Il Kwon ^a   Park, Kyeong Soo ^a,c   Park, Moo Rim ^d   Jo, Deog Yeon ^e   Won, Jong Ho ^f   Kwak, Jae Yong ^g   Kim, Hyeoung Joon ^a,b   Choi, Jin Su ^b   Juhng, Sang Woo ^a   Choi, Chan ^a  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Seonam University   (South Korea)

^d Wonkwang University School of Medicine   (South Korea)

^e Chungnam National University   (South Korea)

^f Soonchunhyang University   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ASIAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETICS; MIDDLE AGED; RISK;

ADULT; AGED; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 77957737909     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2010.1032     Document Type: Article

References (35)

1. Beltinger, C., Kurz, E., Bohler, T., Schrappe, M., Ludwig, W. D., and Debatin, K. M. (1998). CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 91, 3943-3951. (Pubitemid 28225764)
2. Boyle, P., and Levin, B. (2008). World Cancer Report 2008 (International Agency for Research on Cancer, Lyon, France).
3. Drappa, J., Vaishnaw, A. K., Sullivan, K. E., Chu, J. L., and Elkon, K. B. (1996). Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335, 1643-1649.
4. Farre, L., Bittencourt, A. L., Silva-Santos, G., Almeida, A., Silva, A. C., Decanine, D., Soares, G. M., Alcantara, L. C., Jr., Van Dooren, S., Galvao-Castro, B., Vandamme, A. M., and Van Weyenbergh, J. (2008). Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83, 220-222.
5. Gastman, B. R., Atarshi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., and Whiteside, T. L. (1999). Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59, 5356-5364.
6. Gormus, U., Ergen, A., Yilmaz, H., Dalan, B., Berkman, S., and Isbir, T. (2007). Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 27, 991-994.
7. Gronbaek, K., Straten, P. T., Ralfkiaer, E., Ahrenkiel, V., Andersen, M. K., Hansen, N. E., Zeuthen, J., Hou-Jensen, K., and Guldberg, P. (1998). Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92, 3018-3024.
8. Houston, A., and O'Connell, J. (2004). The Fas signaling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4, 321-326.
9. Huang, Q. R., Morris, D., and Manolios, N. (1997). Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34, 577-582.
10. Kalechman, Y., Strassmann, G., Albeck, M., and Sredni, B. (1998). Up-regulation by ammonium trichloro (dioxoethylene-0,00) tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J Immunol 161, 3536-3542.
11. Komada, Y., Zhou, Y. W., Zhang, X. L., Xue, H. L., Sakai, H., Tanaka, S., Sakatoku, H., and Sakurai, M. (1995). Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. Blood 86, 3848-3860.
12. Kumar, V., Abbas, A. K., Fausto, N., and Aster, J. C. (2010). Robbins and Cotran Pathologic Basis of Disease, 8th edition (Saunders, Elsevier, PA).
13. Lai, H. C., Lin, W. Y., Lin, Y. W., Chang, C. C., Yu, M. H., Chen, C. C., and Chu, T. Y. (2005). Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol 99, 113-118.
14. Landowski, T. H., Qu, N., Buyuksal, I., Painter, J. S., and Dalton, W. S. (1997). Mutations in the Fas antigen in patients with multiple myeloma. Blood 90, 4266-4270.
15. Lee, S. H., Shin, M. S., Kim, H. S., Park, W. S., Kim, S. Y., Jang, J. J., Rhim, K. J., Jang, J., Lee, H. K., Park, J. Y., Oh, R. R., Han, S. Y., Lee, J. H., Lee, J. Y., and Yoo, N. J. (2000). Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 114, 122-126.
16. Lee, S. H., Shin, M. S., Park, W. S., Kim, S. Y., Dong, S. M., Pi, J. H., Lee, H. K., Kim, H. S., Jang, J. J., Kim, C. S., Kim, S. H., Lee, J. Y., and Yoo, N. J. (1999a). Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59, 3068-3072.
17. Lee, S. H., Shin, M. S., Park, W. S., Kim, S. Y., Kim, H. S., Han, J. Y., Park, G. S., Dong, S. M., Pi, J. H., Kim, C. S., Kim, S. H., Lee, J. Y., and Yoo, N. J. (1999b). Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18, 3754-3760.
18. Li, C., Wu, W., Liu, J., Qian, L., Li, A., Yang, K., Wei, Q., Zhou, J., and Zhang, Z. (2006). Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 16, 245-251.
19. Liu, Y., Wen, Q. J., Yin, Y., Lu, X. T., Pu, S. H., Tian, H. P., Lou, Y. F., Tang, Y. N., Jiang, X., Lu, G. S., and Zhang, J. (2009). FASLG polymorphism is associated with cancer risk. Eur J Cancer 45, 2574-2578.
20. Maeda, T., Yamadam, Y., Moriuchim, R., Sugaharam, K., Tsurudam, K., Johm, T., Atogamim, S., Tsukasakim, K., Tomonagam, M., and Kamihiram, S. (1999). Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 189, 1063-1071.
21. Ministry of Health, Welfare and Family Affairs. (2009). Annual Report of Cancer Incidence (2007), Cancer Prevalence (2007) and Survival (1993-2007) in Korea. (Seoul, Korea).
22. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
23. Park, S. H., Choi, J. E., Kim, E. J., Jang, J. S., Lee, W. K., Cha, S. I., Kim, C. H., Kam, S., Kim, D. S., Park, R. W., Kim, Y. C., Han, S. B., Jung, T. H., and Park, J. Y. (2006). Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54, 303-308. (Pubitemid 44634149)
24. Shin, M. S., Park, W. S., Kim, S. Y., Kim, H. S., Kang, S. J., Song, K. Y., Park, J. Y., Dong, S. M., Pi, J. H., Oh, R. R., Lee, J. Y., Yoo, N. J., and Lee, S. H. (1999). Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 154, 1785-1791.
25. Sibley, K., Rollinson, S., Allan, J. M., Smith, A. G., Law, G. R., Roddam, P. L., Skibola, C. F., Smith, M. T., and Morgan, G. J. (2003). Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63, 4327-4330.
26. Sun, T., Miao, X., Zhang, X., Tan, W., Xiong, P., and Lin, D. (2004). Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96, 1030-1036.
27. Sun, T., Zhou, Y., Li, H., Han, X., Shi, Y., Wang, L., Miao, X., Tan, W., Zhao, D., Zhang, X., Guo, Y., and Lin, D. (2005). FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202, 967-974.
28. Takayama, H., Takakuwa, T., Tsujimoto, Y., Tani, Y., Nonomura, N., Okuyama, A., Nagata, S., and Aozasa, K. (2002). Frequent Fas gene mutations in testicular germ cell tumors. Am J Pathol 161, 635-641. (Pubitemid 36142172)
29. Tamiya, S., Etoh, K., Suzushima, H., Takatsuki, K., and Matsuoka, M. (1998). Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 91, 3935-3942.
30. Ueda, M., Hung, Y. C., Terai, Y., Yamaguchi, H., Saito, J., Nunobiki, O., Noda, S., and Ueki, M. (2005). Fas gene promoter-670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 98, 129-133.
31. Wu, J., Metz, C, Xu, X., Abe, R., Gibson, A. W., Edberg, J. C., Cooke, J., Xie, F., Cooper, G. S., and Kimberly, R. P. (2003). A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170, 132-138.
32. Zhang, B., Sun, T., Xue, L., Han, X., Zhang, B., Lu, N., Shi, Y., Tan, W., Zhou, Y., Zhao, D., Zhang, X., Guo, Y., and Lin, D. (2007). Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28, 1067-1073.
33. Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y., and Lin, D. (2005). Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42, 479-484.
34. Zhang, Z., Wang, L. E., Sturgis, E. M., El-Naggar, A. K., Hong, W. K., Amos, C. I., Spitz, M. R., and Wei, Q. (2006). Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12, 5596-5602.
35. Zhang, Z., Xue, H., Gong, W., Wang, M., Yuan, L., and Han, S. (2009). FAS promoter polymorphisms and cancer risk: a metaanalysis based on 34 case-control studies. Carcinogenesis 30, 487-493.